ImmunityBio Inc is a trailblazer in the biotechnology sector, focusing on innovative therapies and vaccines to empower the immune system against cancers and infectious diseases. With a rich pipeline that includes immunotherapy, cell therapy, and cutting-edge vaccine technologies, the company is actively advancing treatments for a variety of cancers and pathogens, including COVID-19 and HIV. Based in San Diego, California, ImmunityBio's collaborative efforts extend to notable institutions and companies, aiming to revolutionize healthcare with its groundbreaking research.
ANKTIVA revenue grew 94% year over year for an eighth straight quarter of sequential gains, and the EPS miss came from non-cash charges on warrant and derivative fair value tied to the stock's own climb. An FDA decision on a broader bladder cancer label is set for January 6, 2027.
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally…
